B+
Bull case
20%
Probability
Target price
$31.00
+9.4% vs current
CTEV
ClaritevDNYSE / Health Care Equipment & Services
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$20.50
-27.7% vs current
B-
Bear case
25%
Probability
Target price
$9.50
-66.5% vs current
AI sentiment snapshot
Latest data as of 2026-05-20
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+18.3
Score
AI commentary
Primary-source news flow is constructive on the Q1 update and the PHCS Novera launch, but the setup is still cautious because leverage, ongoing losses, and thin coverage matter more than headline revenue growth. The packet does not include fresh analyst revisions or social coverage, so this remains a monitoring-style name rather than a high-conviction rerating call.
RankAlpha Sentiment Codex - 2026-05-20
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-20catalystQ1 2026 print still anchors near-term tradingMedium impact
Claritev's May 7 first-quarter update reported revenue of $244.7 million (+5.8% YoY), adjusted EBITDA of $146.9 million (+3.4% YoY), and a net loss of $73.6 million, so the stock is still likely to trade on digestion of growth versus profitability and leverage rather than on top-line strength alone [#PR-2026-05-07] [#10-Q-2026-05-07].
2026-12-31eventPHCS Novera rollout can create a 2026 commercialization checkpointHigh impact
The May 13 launch of PHCS Novera says the primary network solution is already available in select markets, with additional market launches planned throughout 2026, giving investors a concrete execution checkpoint for Claritev's network-solutions franchise [#PR-2026-05-13].
2026-12-31catalystDeleveraging and free-cash-flow improvement remain the main rerating leverHigh impact
As of March 31, 2026 Claritev had $21.3 million of cash and cash equivalents, $34.7 million of cash plus restricted cash, $4.6 billion of gross long-term debt, and $218.6 million of remaining revolver availability; the 10-Q says the company was in compliance with debt covenants, so sustained cash-flow improvement is the longer-dated upside case rather than an immediate balance-sheet fix [#10-Q-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-20 • Updated nightlySource: Internal modelMethodology